BioCentury
ARTICLE | Financial News

Epic raises $40M in series D

April 28, 2017 8:45 PM UTC

Liquid biopsy company Epic Sciences Inc. (La Jolla, Calif.) raised $40 million in a series D financing led by Hermed Capital. Also participating were Altos Capital Partners, Domain Associates, Genomic Health Inc. (NASDAQ:GHDX), Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures.

Using its platform, Epic creates phenotypic and genotypic profiles of circulating tumor cells, including biomarker expression and localization, in order to match patients to targeted therapies and monitor drug resistance. The company is developing a test for metastatic castration-resistant prostate cancer (CRPC), OncotypeDx AR-V7 Nucleus Detect, to identify patients that may be resistant to androgen-targeted therapies...